These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis. Li X; Li W; Li Y; Dong C; Zhu P Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675 [TBL] [Abstract][Full Text] [Related]
28. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650 [TBL] [Abstract][Full Text] [Related]
29. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945 [TBL] [Abstract][Full Text] [Related]
30. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O; Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521 [TBL] [Abstract][Full Text] [Related]
31. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. Mader G; Mladsi D; Sanon M; Purser M; Barnett CL; Oberdhan D; Watnick T; Seliger S BMC Nephrol; 2022 Oct; 23(1):334. PubMed ID: 36258169 [TBL] [Abstract][Full Text] [Related]
32. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O Clin J Am Soc Nephrol; 2020 Dec; 16(1):48-58. PubMed ID: 33376102 [TBL] [Abstract][Full Text] [Related]
37. Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease. Cantarelli L; Gutiérrez Valencia M; Leache Alegria L; Sainz Fernandez LC; Erviti Lopez J; Gutiérrez Nicolas F; Nazco Casariego GJ Med Clin (Barc); 2024 Jul; 163(1):1-7. PubMed ID: 38616432 [TBL] [Abstract][Full Text] [Related]
38. Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy. Yamazaki M; Kawano H; Miyoshi M; Kimura T; Takahashi K; Muto S; Horie S Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396765 [TBL] [Abstract][Full Text] [Related]
39. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease. Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E; BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514 [TBL] [Abstract][Full Text] [Related]
40. Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease. Iijima H; Tada T; Hashimoto M; Nishimura T; Kiriki M; Higashiura A; Iwasaki A; Honda M; Nagasawa Y; Yamakado K J Med Ultrason (2001); 2023 Jan; 50(1):81-87. PubMed ID: 36333536 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]